Current and emerging treatment strategies for anal cancer.


Journal Article (Review)

Concurrent radiotherapy and chemotherapy (5-fluorouracil and mitomycin-C) is established as a sphincter-preserving treatment for squamous cell carcinoma of the anal canal. However, there is room for improvement in rates of tumor control as well as a need to reduce treatment-induced toxicity. Efforts are underway to test the value of newer radiosensitizing chemotherapeutic and molecular targeted agents, as well as to establish the value of advances in radiation therapy planning and delivery. This review discusses the evolution of therapy for anal cancer, from early clinical trials establishing the current standard to more recent studies evaluating cisplatin, capecitabine, oxaliplatin, and cetuximab. Early clinical results from studies incorporating intensity-modulated radiation therapy are also discussed.

Full Text

Duke Authors

Cited Authors

  • Meyer, J; Willett, C; Czito, B

Published Date

  • May 2010

Published In

Volume / Issue

  • 12 / 3

Start / End Page

  • 168 - 174

PubMed ID

  • 20425076

Pubmed Central ID

  • 20425076

Electronic International Standard Serial Number (EISSN)

  • 1534-6269

Digital Object Identifier (DOI)

  • 10.1007/s11912-010-0100-9


  • eng

Conference Location

  • United States